Materna Medical Presents a Sub-Analysis Comparing Outcomes on a Spectrum of Menopausal Women, Showing Significant Improvements at Three Months
Materna Medical announced today that an interim menopause-focused sub-analysis from the Prospective On Market Patient-reported Outcomes for Milli (POMPOM) clinical study will be presented at The Menopause Society 2025 Annual Meeting.
Materna Medical Announces Oral Presentation Comparing Outcomes of Dilator-Experienced vs. Naïve Patients from an At-Home Study
Materna Medical announced today that an interim sub-analysis comparing dilator user types from the Prospective On Market Patient-reported Outcomes for Milli (POMPOM) clinical study will be presented orally at the Sexual Medicine Society of North America (SMSNA) Annual Meeting; the sub-analysis suggests a dramatic difference in effectiveness between the two user types.
Materna Medical Presents Interim Data Advancing Understanding of Dilation Therapy on Vaginismus and Related Painful Sex at NPWH Annual Meeting
Materna Medical announced today that interim 3-month results from its Prospective On Market Patient-reported Outcomes for Milli (POMPOM) clinical study will be presented at the Nurse Practitioners in Women’s Health (NPWH) Annual Conference.
Materna Medical Announces New Case Series Highlighting Long-Term Persistence of Pelvic Floor Injuries Following Vaginal Delivery
Materna Medical, a women’s health company pioneering solutions to protect and restore pelvic floor health, announced the presentation of a new case series at the 2025 Society of Ob/Gyn Hospitalists (SOGH) Annual Clinical Meeting, which provides long-term follow-up data confirming the persistence of levator ani muscle avulsions and highlights the risk reduction potential of the Ellora™ Obstetrical System.
Materna Medical Activates All US EASE Prep Pivotal Clinical Trial SitesTop study leadership overseeing novel device related clinical research in OBGYN MOUNTAIN VIEW, CA / ACCESSWIRE / March 31, 2022 / Materna Medical, an OBGYN platform company dedicated to protecting women's pelvic health, announced the completion of the activation of the fifteenth U.S. clinical study site participating in the pivotal EASE trial. This clinical study is evaluating the safety and effectiveness of the Prep device and will investigate
Materna Medical Raises $10 Million in Series A2 Funding in Women's HealthGrowing novel OBGYN platform company that defines a $6B market in the most common pelvic conditions women face MOUNTAIN VIEW, CA / ACCESSWIRE / July 27, 2021 / Materna Medical (Materna), a clinical-stage medical device company, has announced the completion of a $10 million Series A2 financing round. The round was led by Wavemaker Three-Sixty Health (Wavemaker 360) with new investors including Kimera Limited, Women's Venture Capital Fund, Golden
